295 results
Page 10 of 15
8-K
EX-99.1
atdsr03igdcl36t 0uw
25 Oct 11
BioTime CEO Michael D. West to Present Keynote Address at Translational Strategies for Tissue Engineering Conference
12:00am
8-K
EX-99.1
4jg0gj uogg
13 Oct 11
BioTime Publishes Paper Describing First Complete Sequencing of the Nuclear DNA of Five Clinical-Grade Human Embryonic Stem Cell Lines
12:00am
8-K
EX-99.1
tm1zyuo 39
11 Oct 11
BioTime CEO Michael D. West to Present at GTC 2011 5th Advances in Stem Cell Discovery & Development Conference
12:00am
8-K
EX-99.1
c43 sdwdz
4 Oct 11
BioTime Announces Appointment of Chief Financial Officer
12:00am
8-K
EX-99.1
d22m3wnd4a5h
12 Sep 11
BioTime CEO Michael D. West to Present at Stem Cells USA & Regenerative Medicine Congress 2011
12:00am
8-K
EX-99.1
5xwkjq614va
6 Sep 11
Entry into a Material Definitive Agreement
12:00am
8-K
EX-99.1
xy56fno
24 Aug 11
Capital to be utilized in advancing the development of novel cancer diagnostic and therapeutic products
12:00am
8-K
EX-99.1
auzw8npiemnys
19 Aug 11
BioTime Receives NIH Approval for Four GMP Human Embryonic Stem Cell Lines
12:00am
8-K
EX-99.1
j2cbx9ro
10 Aug 11
BioTime Announces Second Quarter 2011 Financial Results and Corporate Developments
12:00am
8-K
EX-99.1
2n8qi2dze0domi
19 Jul 11
BioTime Announces the Issuance of a Second U.S. Glycosan Hydrogel Patent
12:00am
8-K
EX-99.1
vwfg4qxlnu6
15 Jul 11
BioTime Receives $335,900 SBIR Grant
12:00am
8-K
EX-99.1
qtdus9
29 Jun 11
BioTime Announces Appointment of Chief Commercial Officer
12:00am
8-K
EX-99.1
vd6j7dla456nhor6vu
9 Jun 11
Complete sequencing of DNA shows normality of the cells and their suitability for clinical use
12:00am
8-K
EX-99.1
jpjl0 46p
3 Jun 11
BioTime Receives NIH Approval for Two GMP Human Embryonic Stem Cell Lines
12:00am
DEFA14A
i98ib94a pqil
24 May 11
Additional proxy soliciting materials
12:00am
8-K
EX-99.1
anpxhone
10 May 11
BioTime Announces Issuance of U.S. Glycosan Hydrogel Patent
12:00am
8-K
EX-99.1
k1m7y8sgc0rbkujb wb2
5 May 11
BioTime Announces First Quarter 2011 Financial Results and Corporate Developments
12:00am
8-K
EX-99.1
wb892x7qs5i6hfg
3 May 11
BioTime Initiates Clinical Development Program for HyStem®-Rx as a Cell Delivery Device for Reconstructive Surgery and Other Cell-Based Therapies
12:00am